PERSONALISED MEDICINE FOR NEURODEGENERATIVE DISEASES
Basic Information
With the ageing of the world population, the incidence of neurodegenerative diseases is on the rise. At present, an estimated 47 million people are suffering from Alzheimer’s disease and related disorders, the most prevalent class of neurodegenerative diseases. This figure shows no signs of abating, and is expected to double every 20 years as the population ages. One of the greatest challenges for neurodegenerative diseases treatment is the deciphering of the large variability – in origins, mechanisms and clinical expression – that these debilitating diseases are characterised by. With this in mind, JPND has identified a pressing need for investment aimed at enabling research projects on Personalised Medicine, that may in time bring about the delivery of targeted and timely prevention and therapies for patients of neurodegenerative diseases.
| Network | JPCOFUND2 | ||||||||
| Website | https://www.neurodegenerationresearch.eu/initiatives/annual-calls-for-proposals/open-calls/personalised-medicine-2019/ | ||||||||
| Aim of the joint call | The aim of the call is to establish a limited number of ambitious, innovative, multi-national and multi-disciplinary collaborative research projects that address health and social care delivery at the macro level (system and infrastructures) as well as (at) the individual level of patients, their carers and families. Evaluating the strengths and weaknesses of formal and informal care approaches and existing infrastructures is a prelude to implementing improved, evidence-based approaches and thereby improving the quality of life for those affected by neurodegenerative diseases and the quality of care. | ||||||||
| Type of joint call | Two Stages - Call with pre-proposals and full proposals submissions | ||||||||
| Events |
|
||||||||
| Is call co-funded? | Yes | ||||||||
| Call follow up funding | n/a | ||||||||
| Call reasons | n/a | ||||||||
| Research fields |
|
||||||||
| Type of research | n/a | ||||||||
| Target groups |
|
||||||||
| Participating networks |
Organisations Participating
Funded Projects
| Acronym | Title | Start | End | No. partners |
|---|---|---|---|---|
| ADAIR | From air pollution to brain pollution – novel biomarkers to ... | 8 | ||
| DIPPA-FTD | Diagnostic and Prognostic Precision medicine Algorithm for b... | 5 | ||
| E-DADS | Early Detection of Alzheimer’s Disease Subtypes | 6 | ||
| EU-FINGERS | EURO-FINGERS multimodal precision prevention toolbox for dem... | 8 | ||
| GBA-PaCTS | GBA – personalised medicine for Parkinson disease: clinical ... | 6 | ||
| GENFI-prox | Defining measures of proximity to symptom onset in the GENet... | 6 | ||
| Gums&Brain | Alzheimer’s disease as a co-morbidity of chronic periodontit... | 5 | ||
| MIDDEL | Music Interventions for Dementia and Depression in ELderly c... | 5 | ||
| NMJ-Chip | Humanized high-throughput co-culture system for motor neuron... | 8 | ||
| ORGTHERAPY | Multicellular organoids: modeling, mechanisms and therapy de... | 6 | ||
| OligoFIT | Oligomer-Focused screening and Individualized Therapeutics t... | 6 | ||
| PMG-AD | Personalized medicine approach for novel microglia-associate... | 5 | ||
| PMI-AD | Precision Medicine Interventions in Alzheimer’s Disease | 7 | ||
| PREADAPT | Identification of personalized inflammatory profiles of agin... | 7 | ||
| SORLA-FIX | Identifying and treating SORL1-associated Alzheimer’s disease | 5 | ||
| STRATALS | Stratification of presymptomatic amyotrophic lateral scleros... | 5 | ||
| TRIAGE | TRanslating Individual Alzheimer GEnetic risk into disease p... | 4 | ||
| bPRIDE | blood PRotein Identification to Discriminate dEmentias | 7 |